Furthermore, CB-839 sensitized FLT3-ITD AML to the FLT3 tyrosine kinase inhibitor AC220 as shown in in vitro and in vivo studies and revealed the metabolic dependency of FLT3-ITD AML on glutamine metabolism [97,98]. The gene discussed is FLT3; the disease is acute myeloid leukemia.